Shares Outstanding (Quarterly) Chart

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2010. Start Trial.
Date Value
June 30, 2026 39.82M
March 31, 2026 39.31M
December 31, 2025 41.12M
September 30, 2025 42.97M
June 30, 2025 44.90M
March 31, 2025 46.28M
December 31, 2024 46.24M
September 30, 2024 46.15M
June 30, 2024 46.12M
March 31, 2024 46.52M
December 31, 2023 46.48M
September 30, 2023 46.43M
June 30, 2023 46.41M
March 31, 2023 45.97M
December 31, 2022 45.93M
September 30, 2022 45.86M
June 30, 2022 45.80M
March 31, 2022 45.06M
December 31, 2021 44.73M
September 30, 2021 44.52M
June 30, 2021 44.44M
March 31, 2021 43.96M
December 31, 2020 43.64M
September 30, 2020 43.31M
June 30, 2020 42.61M
Date Value
March 31, 2020 42.12M
December 31, 2019 41.91M
September 30, 2019 41.70M
June 30, 2019 41.61M
March 31, 2019 41.29M
December 31, 2018 41.22M
September 30, 2018 41.06M
June 30, 2018 40.96M
March 31, 2018 40.72M
December 31, 2017 40.67M
September 30, 2017 40.56M
June 30, 2017 40.32M
March 31, 2017 40.02M
December 31, 2016 37.48M
September 30, 2016 37.27M
June 30, 2016 37.27M
March 31, 2016 37.10M
December 31, 2015 36.85M
September 30, 2015 36.74M
June 30, 2015 36.61M
March 31, 2015 36.34M
December 31, 2014 36.15M
September 30, 2014 36.02M
June 30, 2014 35.84M
March 31, 2014 33.80M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
Viatris, Inc. 1.155B
Johnson & Johnson 2.408B
Liquidia Corp. 89.10M
Organon & Co. 262.61M
ANI Pharmaceuticals, Inc. 22.97M